# CELLUSION

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellusion

- Industry: Healthcare Specialists
- Headquarters: Tokyo, Japan
- Website: www.cellusion.jp
- Total disclosed funding: $30M
- Latest round: Series C (Jun 7, 2023)
- Investors on record: 12

## About

Based in Japan, Cellusion Inc. focuses on researching and developing innovative regenerative medical technologies aimed at treating bullous keratopathy through advanced cell therapies.Cellusion Inc. was founded in 2015 in Tokyo, Japan, specializing in regenerative medicine with a focus on corneal transplantation solutions. The company has completed four funding rounds, with its most recent being a Series C round on June 7, 2023, raising JPY 2.83 billion. The investors included AIS CAPITAL, Axil Capital Partners, DBJ Capital, and others. Its current valuation stands at JPY 6.18 billion.CELLUSION specializes in developing regenerative medical technologies for bullous keratopathy, providing iPS cell-derived corneal endothelial cells as alternatives to donor corneas. Their innovative cell injection therapy method enhances the transplantation process, targeting ophthalmology professionals and healthcare providers to improve access to advanced treatment options globally.CELLUSION generates revenue through B2B partnerships with healthcare institutions and ophthalmology clinics, selling its iPS cell-derived corneal endothelial cells for transplantation surgeries. The pricing model operates on a per-procedure basis, and the company anticipates further revenue growth as it expands into international markets.In June 2023, CELLUSION Inc. secured JPY 2.83 billion in Series C funding, aimed at bolstering its research and development capabilities and expediting clinical trials. The company plans to launch new products targeted at expanding its offerings in the regenerative medicine sector while exploring new markets, particularly in regions with limited access to donor corneas.

## Funding rounds

- Series C, Jun 7, 2023, $20M — University of Tokyo Edge Capital Partners, SMBC Venture Capital, SPARX Group, Nissay Capital, DBJ Capital, Axil Capital, AIS CAPITAL, Gemseki Inc., JIC Venture Growth Investments
- Series B, Jan 7, 2022, $9.5M — University of Tokyo Edge Capital Partners, SMBC Venture Capital, DBJ Capital, Toho Holdings, Keio Innovation Initiative, Toyo Seikan Group Holdings, Ltd., Gemseki Inc.

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series B, Series C
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series B, Series C
- DBJ Capital (https://capitalatlas.ai/funds/dbj-capital) — Series B, Series C
- Toho Holdings — Series B
- Keio Innovation Initiative (https://capitalatlas.ai/funds/keio-innovation-initiative) — Series B
- Toyo Seikan Group Holdings, Ltd. — Series B
- Gemseki Inc. — Series B, Series C
- SPARX Group (https://capitalatlas.ai/funds/sparx-group) — Series C
- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series C
- Axil Capital (https://capitalatlas.ai/funds/axil-capital) — Series C
- AIS CAPITAL (https://capitalatlas.ai/funds/ais-capital) — Series C
- JIC Venture Growth Investments (https://capitalatlas.ai/funds/jic-venture-growth-investments) — Series C